Search research articles
Contact Us
Filters
Showing results (11-20 of 66) with videos related to
Page
of 7
Sort By:
Therapeutic Advances in Medical Oncology
|
December 6, 2019
Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors
Chiara Casadei, Nazli Dizman, Giuseppe Schepisi, et al.
Cancers
|
March 11, 2023
The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer
Giuseppe Schepisi, Caterina Gianni, Michela Palleschi, et al.
Frontiers in Oncology
|
October 19, 2020
Plasma <i>AR</i> Copy Number Changes and Outcome to Abiraterone and Enzalutamide
Giorgia Gurioli, Vincenza Conteduca, Cristian Lolli, et al.
The Journal of Pathology
|
July 8, 2026
Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of '-mabs'?
Giuseppe Schepisi, Irene Torresan, Emilio Francesco Giunta, et al.
The Oncologist
|
May 27, 2017
A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer
Cristian Lolli, Valentina Gallà, Giuseppe Schepisi, et al.
Expert Opinion on Drug Metabolism & Toxicology
|
March 21, 2018
Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy?
Delia De Lisi, Ugo De Giorgi, Cristian Lolli, et al.
Cancers
|
December 11, 2019
The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment
Nicole Brighi, Alberto Farolfi, Vincenza Conteduca, et al.
Expert Review of Molecular Diagnostics
|
May 27, 2021
An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA
Vincenza Conteduca, Nicole Brighi, Donato Conteduca, et al.
Cancers
|
May 14, 2022
Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
Vincenza Conteduca, Chiara Casadei, Emanuela Scarpi, et al.
Current Cancer Drug Targets
|
November 28, 2017
AR Copy Number and AR Signaling-directed Therapies in Castrationresistant Prostate Cancer
Samanta Salvi, Vincenza Conteduca, Cristian Lolli, et al.
Page
of 7
Search research articles
Search
Showing results (11-20 of 66) with videos related to
Sort By:
Page
of 7
Therapeutic Advances in Medical Oncology
|
December 6, 2019
Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors
Chiara Casadei, Nazli Dizman, Giuseppe Schepisi, et al.
Cancers
|
March 11, 2023
The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer
Giuseppe Schepisi, Caterina Gianni, Michela Palleschi, et al.
Frontiers in Oncology
|
October 19, 2020
Plasma <i>AR</i> Copy Number Changes and Outcome to Abiraterone and Enzalutamide
Giorgia Gurioli, Vincenza Conteduca, Cristian Lolli, et al.
The Journal of Pathology
|
July 8, 2026
Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of '-mabs'?
Giuseppe Schepisi, Irene Torresan, Emilio Francesco Giunta, et al.
The Oncologist
|
May 27, 2017
A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer
Cristian Lolli, Valentina Gallà, Giuseppe Schepisi, et al.
Expert Opinion on Drug Metabolism & Toxicology
|
March 21, 2018
Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy?
Delia De Lisi, Ugo De Giorgi, Cristian Lolli, et al.
Cancers
|
December 11, 2019
The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment
Nicole Brighi, Alberto Farolfi, Vincenza Conteduca, et al.
Expert Review of Molecular Diagnostics
|
May 27, 2021
An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA
Vincenza Conteduca, Nicole Brighi, Donato Conteduca, et al.
Cancers
|
May 14, 2022
Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
Vincenza Conteduca, Chiara Casadei, Emanuela Scarpi, et al.
Current Cancer Drug Targets
|
November 28, 2017
AR Copy Number and AR Signaling-directed Therapies in Castrationresistant Prostate Cancer
Samanta Salvi, Vincenza Conteduca, Cristian Lolli, et al.
Page
of 7